Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.50 |
| ▸ | TSPO | P30536 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12166075 | 0.89 | L3MBTL1 (0.49) | ELANEL3MBTL1F2PLAUKDM4E | |
| SCHEMBL11926707 | 0.82 | MYC (0.52) | ELANETSPOL3MBTL1MYCTSHR | |
| SCHEMBL12166117 | 0.82 | GAA (0.49) | ELANETSPOL3MBTL1KDM4EMYC | |
| SCHEMBL12166069 | 0.80 | MYC (0.45) | ELANEL3MBTL1KDM4EMYCTSHR | |
| SCHEMBL1896211 | 0.79 | HSD17B10 (0.45) | ELANETSPOL3MBTL1KDM4EMYC | |
| SCHEMBL12166108 | 0.79 | HSD17B10 (0.45) | ELANETSPOL3MBTL1KDM4EMYC | |
| SCHEMBL31179907 | 0.78 | MYC (0.56) | ELANEL3MBTL1KDM4EMYCTSHR | |
| SCHEMBL13895889 | 0.76 | TSPO (0.45) | ELANETSPOL3MBTL1TSHRHTT | |
| SCHEMBL12166067 | 0.76 | MYC (0.45) | ELANEL3MBTL1KDM4EMYCTSHR | |
| SCHEMBL12282047 | 0.75 | NR4A2 (0.48) | ELANEKDM4EMYCTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012599-B2 | Nitrogen-containing condensed heterocyclic compounds for OLEDs | MERCK PATENT GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012599-B2 | Nitrogen-containing condensed heterocyclic compounds for OLEDs | MERCK PATENT GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH PATENTS & SCIENTIFIC INFORMATION (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH PATENTS & SCIENTIFIC INFORMATION (DE) | 2012-09-13 | — | — | US | disclosed |
| WO-2011060867-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH (DE) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | OCIAD2, OCIAD1, ODC1 | ELANE 1096/4885TSPO 2385/4885L3MBTL1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.